Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John D Shepherd

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2002
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remissionYves Chalandon, Michael J Barnett, Douglas E Horsman, et al.
Leukemia & Lymphoma|December 25, 2003
Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotypeHaytham Khoury, Bakul I Dalal, Thomas J Nevill, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 8, 2004
Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21)Haytham Khoury, Bakul I Dalal, Stephen H Nantel, et al.
British Journal of Haematology|October 20, 2004
Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantationCynthia L Toze, Michael J Barnett, Joseph M Connors, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 21, 2007
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myelomaJohn Kuruvilla, John D Shepherd, Heather J Sutherland, et al.
Leukemia & Lymphoma|December 24, 2011
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapyAdisak Tantiworawit, Maryse M Power, Michael J Barnett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2006
Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamideAsha Johny, Kevin W Song, Stephen H Nantel, et al.
Pilot and Feasibility Studies|January 28, 2026
A pilot randomised controlled trial of the Spinal Cord Injury and You (SCI&U) online peer health coaching self-management programSusan B Jaglal, Sonya J Allin, B Catharine Craven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantationDonna L Forrest, Donna E Hogge, Thomas J Nevill, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2002
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remissionYves Chalandon, Michael J Barnett, Douglas E Horsman, et al.
Leukemia & Lymphoma|December 25, 2003
Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotypeHaytham Khoury, Bakul I Dalal, Thomas J Nevill, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 8, 2004
Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21)Haytham Khoury, Bakul I Dalal, Stephen H Nantel, et al.
British Journal of Haematology|October 20, 2004
Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantationCynthia L Toze, Michael J Barnett, Joseph M Connors, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 21, 2007
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myelomaJohn Kuruvilla, John D Shepherd, Heather J Sutherland, et al.
Leukemia & Lymphoma|December 24, 2011
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapyAdisak Tantiworawit, Maryse M Power, Michael J Barnett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2006
Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamideAsha Johny, Kevin W Song, Stephen H Nantel, et al.
Pilot and Feasibility Studies|January 28, 2026
A pilot randomised controlled trial of the Spinal Cord Injury and You (SCI&U) online peer health coaching self-management programSusan B Jaglal, Sonya J Allin, B Catharine Craven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantationDonna L Forrest, Donna E Hogge, Thomas J Nevill, et al.
Pageof 4